NoTremor
Virtual, Physiological and Computational Neuromuscular Models for the Predictive Treatment of Parkinson'snDisease
| Coordinatore | ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
Organization address
address: CHARILAOU THERMI ROAD 6th Km contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Totale costo | 4˙181˙071 € |
| EC contributo | 2˙942˙000 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2013-10 |
| Funding Scheme | CP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
Organization address
address: CHARILAOU THERMI ROAD 6th Km contact info |
EL (THERMI THESSALONIKI) | coordinator | 0.00 |
| 2 |
PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG
Organization address
address: VAUXHALL BRIDGE RAOD contact info |
UK (LONDON) | participant | 0.00 |
| 3 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 4 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 0.00 |
| 5 |
UCB PHARMA SA
Organization address
address: ALLEE DE LA RECHERCHE contact info |
BE (BRUXELLES) | participant | 0.00 |
| 6 |
UNIVERSITA DEGLI STUDI DI TRENTO
Organization address
address: VIA BELENZANI contact info |
IT (TRENTO) | participant | 0.00 |
| 7 |
UNIVERSITY OF PATRAS
Organization address
address: UNIVERSITY CAMPUS RIO PATRAS contact info |
EL (RIO PATRAS) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
NoTremor aims to provide patient specific computational models of the coupled brain and neuromuscular systems that will be subsequently used to improve the quality of analysis, prediction and progression of Parkinson's disease. In particular, it aspires to establish the neglected link between brain modelling and neuromuscular systems that will result in a holistic representation of the physiology for PD patients. A significant breakthrough of NoTremor is that these models will not be used for abstract representation of the physiology or as a match between theory and clinical measurements. On the contrary, they will be used with a totally new perspective; predictive simulation. NoTremor will integrate computational models of the basal ganglia and brainstem into a unique multi-scale parametric computational model that can be subsequently simulated in the NoTremor simulation engine in a physics-based manner. NoTremor will revolutionize research in the pathophysiology of neurodegenerative movement disorders and provide a novel approach for their analysis founded on a solid computational modelling basis that links midbrain degenerations to motor behaviour. The computational models will be quantified and validated through test campaigns with a very large cohort of PD patients. The impact of such a groundbreaking approach is huge and the foundations laid here are expected to result in a widespread adoption of predictive simulation not only in PD, but also in other neurodegenerative diseases. The ultimate challenging use of the NoTremor developments will be from the one side clinical decision support and from the other side the investigation, virtual prototyping and testing of new drugs using virtual patient models. UCB Pharma aims to incorporate the NoTremor computational modelling and simulation approach in their drug development pipeline that is expected to significantly boost the efficiency and personalization of new drugs.